Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate
| Autor: | Denise Williams, N. Mody-Patel, Victoria Barghout, R. Halpern |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cancer Research
medicine.medical_specialty GiST business.industry medicine.drug_class Myeloid leukemia Pharmacy Imatinib medicine.disease Comorbidity Tyrosine-kinase inhibitor Surgery Imatinib mesylate Oncology hemic and lymphatic diseases Internal medicine Medicine Stromal tumor business neoplasms medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:6598-6598 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.6598 |
| Popis: | 6598 Background: Imatinib mesylate is an oral tyrosine kinase inhibitor dosed daily for treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). The relationships between imatinib compliance and costs and inpatient hospitalizations (IP hosp) for CML and GIST patients (pts) were analyzed with multivariate regression. Methods: Claims data from a large national US health plan were used. Pts had ≥2 imatinib claims from 6/1/01–3/31/05; ≥1-year follow-up (F-U) after 1st imatinib claim; and diagnosis of CML (ICD9 205.1x) or GIST (ICD9 159.0, 159.8, 159.9 or evaluation of claims history and attribution of GIST by independent hematologist/oncologist). Compliance measure was medication possession ratio ((days of imatinib during F- U/days of F-U)*100). Compliance categories were: good, ≥90%; medium, 70–89.9%; poor |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|